Plasma Bioengineering Myths

Bioengineering is full of oversimplifications.

00:00 Intro
01:03 About Me
02:07 Myth: More Power = More Effect
04:16 Myth: In Vitro = In Vivo
06:43 Myth: Reactive Species Are Always Harmful
09:37 Myth: Mechanism Is Obvious
11:39 Myth: If It Works Once, It Scales
13:52 Myth: Plasma Is Just Oxidation
14:46 Myth: Biological Systems Are Simple Targets
17:07 Myth: Regulatory Approval Means Mechanism Is Fully Understood
19:21 Myth: Innovation Is Purely Scientific
20:55 What Actually Matters
21:57 Closing Thoughts

In this episode, I break down common myths that show up in research papers, startups, and even academic labs:

• “More power = more effect”
• “In vitro results translate directly to patients”
• “Reactive species are always harmful”
• “If it works once, it scales”
• “Plasma is just oxidation”

We’ll talk about dose-response behavior, mechanistic rigor, nonlinear biology, scaling challenges, and why systems thinking matters.

I’ve spent over a decade as a research professor and now run an R&D company focused on plasma systems for medical and environmental applications. This is a calm, technically grounded conversation about where bioengineering narratives often drift away from reality.

If you enjoy serious discussions about science without hype, this channel is for you.

Please report errors, omissions, comments, & suggestions in the comments below, by email at greg@aaplasma.com, or
@gregfridman on socials.

https://scholar.google.com/citations?user=fNk59nMAAAAJ
https://www.linkedin.com/in/gregfridman/
https://www.facebook.com/gregfridman
https://twitter.com/gregfridman

Видео Plasma Bioengineering Myths канала Chat with Greg Fridman